Extracellular adenosine: A safety signal that dampens hypoxia-induced inflammation during ischemia

Antioxidants and Redox Signaling

Volumn 15, Issue 8, 2011, Pages 2221-2234

  Grenz, Almut ^a   Homann, Dirk ^b   Eltzschig, Holger K ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE RECEPTOR; NETRIN 1; NUCLEOTIDE; OXYGEN;

EXTRACELLULAR SPACE; HEART MUSCLE ISCHEMIA; HUMAN; HYDROLYSIS; HYPOXIA; IMMUNE RESPONSE; INFLAMMATION; INFLAMMATORY CELL; ISCHEMIA; KIDNEY ISCHEMIA; LIVER ISCHEMIA; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SIGNAL PROCESSOR; SIGNAL TRANSDUCTION;

ADENOSINE; ANIMALS; ANOXIA; HUMANS; INFLAMMATION; ISCHEMIA; SIGNAL TRANSDUCTION;

EID: 79960698249     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2010.3665     Document Type: Review

References (124)

1. Aherne CM, Kewley EM, and Eltzschig HK. The resurgence of A2B adenosine receptor signaling. Biochim Biophys Acta 2010 [Epub ahead of print].
2. Ahmad A, Ahmad S, Glover L, Miller SM, Shannon JM, Guo X, Franklin WA, Bridges JP, Schaack JB, Colgan SP, and White CW. Adenosine A2A receptor is a unique angiogenic target of HIF-2alpha in pulmonary endothelial cells. Proc Natl Acad Sci USA 106: 10684-10689, 2009.
3. Blackburn MR. Too much of a good thing: adenosine overload in adenosine-deaminase-deficient mice. Trends Pharmacol Sci 24: 66-70, 2003. (Pubitemid 36135878)
4. Blackburn MR, Vance CO, Morschl E, and Wilson CN. Adenosine receptors and inflammation. Handb Exp Pharmacol 193: 215-269, 2009.
5. Burnstock G. Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol 22: 364-373, 2002. (Pubitemid 34218740)
6. Burnstock G. Vessel tone and remodeling. Nat Med 12: 16-17, 2006. (Pubitemid 43050963)
7. Burnstock G. Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov 7: 575-590, 2008. (Pubitemid 351927723)
8. Castrop H, Huang Y, Hashimoto S, Mizel D, Hansen P, Theilig F, Bachmann S, Deng C, Briggs J, and Schnermann J. Impairment of tubuloglomerular feedback regulation of GFR in ecto-5'-nucleotidase/CD73-deficient mice. J Clin Invest 114: 634-642, 2004. (Pubitemid 39578753)
9. Chen H, Yang D, Carroll SH, Eltzschig HK, and Ravid K. Activation of the macrophage A2b adenosine receptor regulates tumor necrosis factor-alpha levels following vascular injury. Exp Hematol 37: 533-538, 2009.
10. Cirulli V and Yebra M. Netrins: beyond the brain. Nat Rev Mol Cell Biol 8: 296-306, 2007. (Pubitemid 46474658)
11. Colgan SP, Eltzschig HK, Eckle T, and Thompson LF. Physiological Roles of 5'-Ectonucleotidase (CD73). Purinergic Signal 2: 351-360, 2006.
12. Colgan SP and Taylor CT. Hypoxia: an alarm signal during intestinal inflammation. Nat Rev Gastroenterol Hepatol 7: 281-287, 2010.
13. Corset V, Nguyen-Ba-Charvet KT, Forcet C, Moyse E, Chedotal A, and Mehlen P. Netrin-1-mediated axon outgrowth and cAMP production requires interaction with adenosine A2b receptor. Nature 407: 747-750, 2000.
14. Cronstein BN, Naime D, and Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 92: 2675-2682, 1993. (Pubitemid 24006532)
15. Day YJ, Huang L, McDuffie MJ, Rosin DL, Ye H, Chen JF, Schwarzschild MA, Fink JS, Linden J, and Okusa MD. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest 112: 883-891, 2003. (Pubitemid 38063746)
16. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, Kuchroo VK, Strom TB, and Robson SC. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204: 1257-1265, 2007. (Pubitemid 46919862)
17. Decking UKM, Schlieper G, Kroll K, and Schrader J. Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Circ Res 81: 154-164, 1997. (Pubitemid 27342482)
18. Delacretaz E. Clinical practice. Supraventricular tachycardia. N Engl J Med 354: 1039-1051, 2006.
19. Dieterich HJ, Weissmuller T, Rosenberger P, and Eltzschig HK. Effect of hydroxyethyl starch on vascular leak syndrome and neutrophil accumulation during hypoxia. Crit Care Med 34: 1775-1782, 2006. (Pubitemid 43810062)
20. Drury AN and Szent-Gyorgyi A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J Physiol 68: 213-237, 1929.
21. Eckle T, Faigle M, Grenz A, Laucher S, Thompson LF, and Eltzschig HK. A2B adenosine receptor dampens hypoxiainduced vascular leak. Blood 111: 2024-2035, 2008. (Pubitemid 351451513)
22. Eckle T, Fullbier L, Wehrmann M, Khoury J, Mittelbronn M, Ibla J, Rosenberger P, and Eltzschig HK. Identification of ectonucleotidases CD39 and CD73 in innate protection during acute lung injury. J Immunol 178: 8127-8137, 2007. (Pubitemid 46898085)
23. Eckle T, Grenz A, Laucher S, and Eltzschig HK. A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. J Clin Invest 118: 3301-3315, 2008.
24. Eckle T, Koeppen M, and Eltzschig HK. Role of extracellular adenosine in acute lung injury. Physiology (Bethesda) 24: 298-306, 2009.
25. Eckle T, Kohler D, Lehmann R, El Kasmi KC, and Eltzschig HK. Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation 118: 166-175, 2008.
26. Eckle T, Krahn T, Grenz A, Kohler D, Mittelbronn M, Ledent C, Jacobson MA, Osswald H, Thompson LF, Unertl K, and Eltzschig HK. Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation 115: 1581-1590, 2007. (Pubitemid 46648643)
27. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, Park D, Woodson RI, Ostankovich M, Sharma P, Lysiak JJ, Harden TK, Leitinger N, and Ravichandran KS. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461: 282-286, 2009.
28. Eltzschig HK. Adenosine: an old drug newly discovered. Anesthesiology 111: 904-915, 2009.
29. Eltzschig HK, Abdulla P, Hoffman E, Hamilton KE, Daniels D, Schonfeld C, Loffler M, Reyes G, Duszenko M, Karhausen J, Robinson A, Westerman KA, Coe IR, and Colgan SP. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J Exp Med 202: 1493-1505, 2005. (Pubitemid 41746596)
30. Eltzschig HK and Collard CD. Vascular ischaemia and reperfusion injury. Br Med Bull 70: 71-86, 2004. (Pubitemid 40069373)
31. Eltzschig HK, Eckle T, Mager A, Kuper N, Karcher C, Weissmuller T, Boengler K, Schulz R, Robson SC, and Colgan SP. ATP release from activated neutrophils occurs via connexin 43 and modulates adenosine-dependent endothelial cell function. Circ Res 99: 1100-1108, 2006. (Pubitemid 44729934)
32. Eltzschig HK, Faigle M, Knapp S, Karhausen J, Ibla J, Rosenberger P, Odegard KC, Laussen PC, Thompson LF, and Colgan SP. Endothelial catabolism of extracellular adenosine during hypoxia: the role of surface adenosine deaminase and CD26. Blood 108: 1602-1610, 2006. (Pubitemid 44316128)
33. Eltzschig HK, Ibla JC, Furuta GT, Leonard MO, Jacobson KA, Enjyoji K, Robson SC, and Colgan SP. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med 198: 783-796, 2003. (Pubitemid 37087777)
34. Eltzschig HK, Kohler D, Eckle T, Kong T, Robson SC, and Colgan SP. Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. Blood 113: 224-232, 2009.
35. Eltzschig HK, Macmanus CF, and Colgan SP. Neutrophils as sources of extracellular nucleotides: functional consequences at the vascular interface. Trends Cardiovasc Med 18: 103-107, 2008. (Pubitemid 351626607)
36. Eltzschig HK, Rivera-Nieves J, and Colgan SP. Targeting the A2B adenosine receptor during gastrointestinal ischemia and inflammation. Expert Opin Ther Targets 13: 1267-1277, 2009.
37. Eltzschig HK, Thompson LF, Karhausen J, Cotta RJ, Ibla JC, Robson SC, and Colgan SP. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood 104: 3986-3992, 2004. (Pubitemid 39620148)
38. Enjyoji K, Sevigny J, Lin Y, Frenette PS, Christie PD, Esch JS 2nd, Imai M, Edelberg JM, Rayburn H, Lech M, Beeler DL, Csizmadia E, Wagner DD, Robson SC, and Rosenberg RD. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 5: 1010-1017, 1999. (Pubitemid 29439571)
39. Faigle M, Seessle J, Zug S, El Kasmi KC, and Eltzschig HK. ATP release from vascular endothelia occurs across Cx43 hemichannels and is attenuated during hypoxia. PLoS ONE 3: e2801, 2008.
40. Frangogiannis NG, Ren G, Dewald O, Zymek P, Haudek S, Koerting A, Winkelmann K, Michael LH, Lawler J, and Entman ML. Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation 111: 2935-2942, 2005. (Pubitemid 40814186)
41. Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 14: 1315-1323, 2007. (Pubitemid 46965261)
42. Frick JS, MacManus CF, Scully M, Glover LE, Eltzschig HK, and Colgan SP. Contribution of adenosine A2B receptors to inflammatory parameters of experimental colitis. J Immunol 182: 4957-4964, 2009.
43. Grenz A, Osswald H, Eckle T, Yang D, Zhang H, Tran ZV, Klingel K, Ravid K, and Eltzschig HK. The reno-vascular A2B adenosine receptor protects the kidney from ischemia. PLoS Medicine 5: e137, 2008.
44. Grenz A, Zhang H, Eckle T, Mittelbronn M, Wehrmann M, Kohle C, Kloor D, Thompson LF, Osswald H, and Eltzschig HK. Protective role of ecto-5'-nucleotidase (CD73) in renal ischemia. J Am Soc Nephrol 18: 833-845, 2007. (Pubitemid 46434500)
45. Grenz A, Zhang H, Hermes M, Eckle T, Klingel K, Huang DY, Muller CE, Robson SC, Osswald H, and Eltzschig HK. Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury. FASEB J 21: 2863-2873, 2007. (Pubitemid 47372753)
46. Haeberle HA, Durrstein C, Rosenberger P, Hosakote YM, Kuhlicke J, Kempf VA, Garofalo RP, and Eltzschig HK. Oxygen-independent stabilization of hypoxia inducible factor (HIF)-1 during RSV infection. PLoS ONE 3: e3352, 2008.
47. Hart M, Jacobi B, Schittenhelm J, Henn M, and Eltzschig HK. A2B adenosine receptor signaling provides potent protection during intestinal ischemia/reperfusion injury. J Immunol 182: 3965-3968, 2009.
48. Hart ML, Gorzolla IC, Schittenhelm J, Robson SC, and Eltzschig HK. SP1-dependent induction of CD39 facilitates hepatic ischemic preconditioning. J Immunol 184: 4017-4024, 2010.
49. Hart ML, Henn M, Kohler D, Kloor D, Mittelbronn M, Gorzolla IC, Stahl GL, and Eltzschig HK. Role of extracellular nucleotide phosphohydrolysis in intestinal ischemiareperfusion injury. FASEB J 22: 2784-2797, 2008.
50. Hart ML, Jacobi B, Schittenhelm J, Henn M, and Eltzschig HK. Cutting edge: A2B adenosine receptor signaling provides potent protection during intestinal ischemia/reperfusion injury. J Immunol 182: 3965-3968, 2009.
51. Hart ML, Kohler D, Eckle T, Kloor D, Stahl GL, and Eltzschig HK. Direct treatment of mouse or human blood with soluble 5'-nucleotidase inhibits platelet aggregation. Arterioscler Thromb Vasc Biol 28: 1477-1483, 2008.
52. Hart ML, Much C, Gorzolla IC, Schittenhelm J, Kloor D, Stahl GL, and Eltzschig HK. Extracellular adenosine production by ecto-5'-nucleotidase protects during murine hepatic ischemic preconditioning. Gastroenterology 135: 1739-1750.e3, 2008.
53. Hartmann H, Eltzschig HK, Wurz H, Hantke K, Rakin A, Yazdi AS, Matteoli G, Bohn E, Autenrieth IB, Karhausen J, Neumann D,ColganSP,andKempfVA.Hypoxia- independent activationofHIF-1by enterobacteriaceae andtheir siderophores. Gastroenterology 134: 756-767, 2008.
54. Hasko G, Csoka B, Nemeth ZH, Vizi ES, and Pacher P. A(2B) adenosine receptors in immunity and inflammation. Trends Immunol 30: 263-270, 2009.
55. Hasko G, Linden J, Cronstein B, and Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7: 759-770, 2008.
56. Herrmann HC. Update and rationale for ongoing acute myocardial infarction trials: combination therapy, facilitation, and myocardial preservation. Am Heart J 151: S30-S39, 2006. (Pubitemid 44183728)
57. Holmquist-Mengelbier L, Fredlund E, Lofstedt T, Noguera R, Navarro S, Nilsson H, Pietras A, Vallon-Christersson J, Borg A, Gradin K, Poellinger L, and Pahlman S. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 10: 413-423, 2006. (Pubitemid 44693470)
58. Hu CJ, Wang LY, Chodosh LA, Keith B, and Simon MC. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 23: 9361-9374, 2003. (Pubitemid 37499822)
59. Jackson EK, Ren J, Gillespie DG, and Dubey RK. Extracellular 2',3'-cyclic adenosine 5'-monophosphate is a potent inhibitor of preglomerular vascular smooth muscle cell and mesangial cell growth. Hypertension 56: 151-158, 2010.
60. Jackson EK, Ren J, and Mi Z. Extracellular 2',3'-cAMP is a source of adenosine. J Biol Chem 284: 33097-33106, 2009.
61. Kim M, Chen SW, Park SW, D'Agati VD, Yang J, and Lee HT. Kidney-specific reconstitution of the A1 adenosine receptor in A1 adenosine receptor knockout mice reduces renal ischemia-reperfusion injury. Kidney Int 75: 809-823, 2009.
62. Kitakaze M, Hori M, Morioka T, Minamino T, Takashima S, Sato H, Shinozaki Y, Chujo M, Mori H, Inoue M, et al. Infarct size-limiting effect of ischemic preconditioning is blunted by inhibition of 5'-nucleotidase activity and attenuation of adenosine release. Circulation 89: 1237-1246, 1994.
63. Kloner RA and Rezkalla SH. Preconditioning, postconditioning and their application to clinical cardiology. Cardiovasc Res 70: 297-307, 2006.
64. Koeppen M, Eckle T, and Eltzschig HK. Selective deletion of the A1 adenosine receptor abolishes heart-rate slowing effects of intravascular adenosine in vivo. PLoS ONE 4: e6784, 2009.
65. Kohler D, Eckle T, Faigle M, Grenz A, Mittelbronn M, Laucher S, Hart ML, Robson SC, Muller CE, and Eltzschig HK. CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury. Circulation 116: 1784-1794, 2007. (Pubitemid 350287103)
66. Kong T, Eltzschig HK, Karhausen J, Colgan SP, and Shelley CS. Leukocyte adhesion during hypoxia is mediated by HIF-1-dependent induction of {beta}2 integrin gene expression. PNAS 101: 10440-10445, 2004. (Pubitemid 38924944)
67. Kong T, Westerman KA, Faigle M, Eltzschig HK, and Colgan SP. HIF-dependent induction of adenosine A2B receptor in hypoxia. FASEB J 20: 2242-2250, 2006. (Pubitemid 44953854)
68. Koszalka P, Ozuyaman B, Huo Y, Zernecke A, Flogel U, Braun N, Buchheiser A, Decking UK, Smith ML, Sevigny J, Gear A, Weber AA, Molojavyi A, Ding Z, Weber C, Ley K, Zimmermann H, Godecke A, and Schrader J. Targeted disruption of cd73/ecto-5'-nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ Res 95: 814-821, 2004. (Pubitemid 39390584)
69. Kruger B, Krick S, Dhillon N, Lerner SM, Ames S, Bromberg JS, Lin M, Walsh L, Vella J, Fischereder M, Kramer BK, Colvin RB, Heeger PS, Murphy BT, and Schroppel B. Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci USA 106: 3390-3395, 2009.
70. Kuhlicke J, Frick JS, Morote-Garcia JC, Rosenberger P, and Eltzschig HK. Hypoxia inducible factor (HIF)-1 Coordinates induction of Toll-like receptors TLR2 and TLR6 during Hypoxia. PLoS ONE 2: e1364, 2007.
71. Lappas CM, Day YJ, Marshall MA, Engelhard VH, and Linden J. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1ddependent NKT cell activation. J Exp Med 203: 2639-2648, 2006. (Pubitemid 44833340)
72. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ, Costentin J, Heath JK, Vassart G, and Parmentier M. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388: 674-678, 1997. (Pubitemid 27366438)
73. Loffler M, Morote-Garcia JC, Eltzschig SA, Coe IR, and Eltzschig HK. Physiological roles of vascular nucleoside transporters. Arterioscler Thromb Vasc Biol 27: 1004-1013, 2007. (Pubitemid 46641985)
74. Ly NP, Komatsuzaki K, Fraser IP, Tseng AA, Prodhan P, Moore KJ, and Kinane TB. Netrin-1 inhibits leukocyte migration in vitro and in vivo. Proc Natl Acad Sci USA 102: 14729-14734, 2005. (Pubitemid 41457124)
75. Marcus AJ, Broekman MJ, Drosopoulos JHF, Islam N, Alyonycheva TN, Safier LB, Hajjar KA, Posnett DN, Schoenborn MA, Schooley KA, Gayle RB, and Maliszewski CR. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest 99: 1351-1360, 1997. (Pubitemid 27142773)
76. Matherne GP, Linden J, Byford AM, Gauthier NS, and Headrick JP. Transgenic A1 adenosine receptor overexpression increases myocardial resistance to ischemia. Proc Natl Acad Sci USA 94: 6541-6546, 1997. (Pubitemid 27270721)
77. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 12: 991-1045, 1994. (Pubitemid 24140436)
78. Matzinger P. The danger model: a renewed sense of self. Science 296: 301-305, 2002. (Pubitemid 34303674)
79. Mohamedali KA, Guicherit OM, Kellems RE, and Rudolph FB. The highest levels of purine catabolic enzymes in mice are present in the proximal small intestine. J Biol Chem 268: 23728-23733, 1993. (Pubitemid 23328108)
80. Montesinos MC, Desai A, Delano D, Chen JF, Fink JS, Jacobson MA, and Cronstein BN. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 48: 240-247, 2003. (Pubitemid 36091669)
81. Morote-Garcia JC, Rosenberger P, Kuhlicke J, and Eltzschig HK. HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak. Blood 111: 5571-5580, 2008.
82. Morote-Garcia JC, Rosenberger P, Nivillac NM, Coe IR, and Eltzschig HK. Hypoxia-inducible factor-dependent repression of equilibrative nucleoside transporter 2 attenuates mucosal inflammation during intestinal hypoxia. Gastroenterology 136: 607-618, 2009.
83. Murry CE, Jennings RB, and Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136, 1986. (Pubitemid 17174962)
84. Niemela J, Ifergan I, Yegutkin GG, Jalkanen S, Prat A, and Airas L. IFN-beta regulates CD73 and adenosine expression at the blood-brain barrier. Eur J Immunol 38: 2718-2726, 2008.
85. Ohta A and Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414: 916-920, 2001. (Pubitemid 34024743)
86. Park SW, Chen SW, Kim M, Brown KM, D'Agati VD, and Lee HT. Protection against acute kidney injury via A1 adenosine receptor-mediated Akt activation reduces liver injury after liver ischemia and reperfusion in mice. J Pharmacol Exp Ther 333: 736-747, 2010.
87. Peng Z, Borea PA, Wilder T, Yee H, Chiriboga L, Blackburn MR, Azzena G, Resta G, and Cronstein BN. Adenosine signaling contributes to ethanol-induced fatty liver in mice. J Clin Invest 119: 582-594, 2009.
88. Picher M, Burch LH, Hirsh AJ, Spychala J, and Boucher RC. Ecto 5'-nucleotidase and nonspecific alkaline phosphatase. Two AMP-hydrolyzing ectoenzymes with distinct roles in human airways. J Biol Chem 278: 13468-13479, 2003. (Pubitemid 36800121)
89. Pinsky DJ, Broekman MJ, Peschon JJ, Stocking KL, Fujita T, Ramasamy R, Connolly ES, Jr., Huang J, Kiss S, Zhang Y, Choudhri TF, McTaggart RA, Liao H, Drosopoulos JH, Price VL, Marcus AJ, and Maliszewski CR. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. J Clin Invest 109: 1031-1040, 2002. (Pubitemid 34408578)
90. Rankin EB, Biju MP, Liu Q, Unger TL, Rha J, Johnson RS, Simon MC, Keith B, and Haase VH. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest 117: 1068-1077, 2007. (Pubitemid 46556763)
91. Ratcliffe PJ. HIF-1 and HIF-2: working alone or together in hypoxia? J Clin Invest 117: 862-865, 2007. (Pubitemid 46556739)
92. Reichelt ME, Shanu A, Willems L, Witting PK, Ellis NA, Blackburn MR, and Headrick JP. Endogenous adenosine selectively modulates oxidant stress via the A1 receptor in ischemic hearts. Antioxid Redox Signal 11: 2641-2650, 2009.
93. Reichelt ME, Willems L, Molina JG, Sun CX, Noble JC, Ashton KJ, Schnermann J, Blackburn MR, and Headrick JP. Genetic deletion of the A1 adenosine receptor limits myocardial ischemic tolerance. Circ Res 96: 363-367, 2005. (Pubitemid 40279911)
94. Reutershan J, Vollmer I, Stark S, Wagner R, Ngamsri KC, and Eltzschig HK. Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. FASEB J 23: 473-482, 2009.
95. Robson SC, Wu Y, Sun X, Knosalla C, Dwyer K, and Enjyoji K. Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin Thromb Hemost 31: 217-233, 2005. (Pubitemid 40605196)
96. Rose JB, Naydenova Z, Bang A, Eguchi M, Sweeney G, Choi DS, Hammond JR, and Coe IR. Equilibrative Nucleoside Transporter 1 (ENT1) plays an essential role in cardioprotection. Am J Physiol Heart Circ Physiol 298: H771-H777, 2010.
97. Rosenberger P, Schwab JM, Mirakaj V, Masekowsky E, Mager A, Morote-Garcia JC, Unertl K, and Eltzschig HK. Hypoxia-inducible factor-dependent induction of netrin-1 dampens inflammation caused by hypoxia. Nat Immunol 10: 195-202, 2009.
98. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlof B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, and Yoon BW. Aspirin and extendedrelease dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 359: 1238-1251, 2008.
99. Salvatore CA, Tilley SL, Latour AM, Fletcher DS, Koller BH, and Jacobson MA. Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J Biol Chem 275: 4429-4434, 2000. (Pubitemid 30094686)
100. Schingnitz U, Hartmann K, Macmanus CF, Eckle T, Zug S, Colgan SP, and Eltzschig HK. Signaling through the A2B adenosine receptor dampens endotoxin-induced acute lung injury. J Immunol 184: 5271-5279, 2010.
101. Schofield CJ and Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5: 343-354, 2004. (Pubitemid 38579472)
102. Schroder K and Tschopp J. The inflammasomes. Cell 140: 821-832.
103. Serafini T, Colamarino SA, Leonardo ED, Wang H, Beddington R, Skarnes WC, and Tessier-Lavigne M. Netrin-1 is required for commissural axon guidance in the developing vertebrate nervous system. Cell 87: 1001-1014, 1996. (Pubitemid 26427984)
104. Sitkovsky M and Lukashev D. Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors. Nat Rev Immunol 5: 712-721, 2005. (Pubitemid 43086172)
105. Sitkovsky MV. T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol 30: 102-108, 2009.
106. Sitkovsky MV, Kjaergaard J, Lukashev D, and Ohta A. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res 14: 5947-5952, 2008.
107. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, Ohta A, and Thiel M. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 22: 657-682, 2004. (Pubitemid 38680437)
108. Suadicani SO, Brosnan CF, and Scemes E. P2X7 receptors mediate ATP release and amplification of astrocytic intercellular Ca2 + signaling. J Neurosci 26: 1378-1385, 2006. (Pubitemid 43237008)
109. Sun CX, Zhong H, Mohsenin A, Morschl E, Chunn JL, Molina JG, Belardinelli L, Zeng D, and Blackburn MR. Role ofA2Badenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest 116: 2173-2182, 2006. (Pubitemid 44162326)
110. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, Hansen KR, Thompson LF, and Colgan SP. Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 110: 993-1002, 2002.
111. Thiel M, Chouker A, Ohta A, Jackson E, Caldwell C, Smith P, Lukashev D, Bittmann I, and Sitkovsky MV. Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol 3: e174, 2005.
112. Thompson LF, Eltzschig HK, Ibla JC, Van De Wiele CJ, Resta R, Morote-Garcia JC, and Colgan SP. Crucial role for ecto-5'-nucleotidase (CD73) in vascular leakage during hypoxia. J Exp Med 200: 1395-1405, 2004. (Pubitemid 39657287)
113. Walsh MC, Bourcier T, Takahashi K, Shi L, Busche MN, Rother RP, Solomon SD, Ezekowitz RA, and Stahl GL. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol 175: 541-546, 2005. (Pubitemid 40884360)
114. Wang ECY, Lee J-M, Ruiz WG, Balestreire EM, von Bodungen M, Barrick S, Cockayne DA, Birder LA, and Apodaca G. ATP and purinergic receptor-dependent membrane traffic in bladder umbrella cells. J Clin Invest 115: 2412-2422, 2005. (Pubitemid 41266203)
115. Wang G, Jiang B, Rue E, and Semenza G. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2tension. Proc Natl Acad SciUSA92: 5510-5514, 1995.
116. Wellmann S, Bettkober M, Zelmer A, Seeger K, Faigle M, Eltzschig HK, and Buhrer C. Hypoxia upregulates the histone demethylase JMJD1A via HIF-1. Biochem Biophys Res Commun 372: 892-897, 2008.
117. Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J 16: 1151-1162, 2002. (Pubitemid 34815403)
118. Yang D, Koupenova M, McCrann DJ, Kopeikina KJ, Kagan HM, Schreiber BM, and Ravid K. The A2b adenosine receptor protects against vascular injury. Proc Natl Acad Sci USA 105: 792-796, 2008. (Pubitemid 351171787)
119. Yang D, Zhang Y, Nguyen HG, Koupenova M, Chauhan AK, Makitalo M, Jones MR, St. Hilaire C, Seldin DC, Toselli P, Lamperti E, Schreiber BM, Gavras H, Wagner DD, and Ravid K. The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest 116: 1913-1923, 2006. (Pubitemid 44033315)
120. Yang JN, Chen JF, and Fredholm BB. Physiological roles of A1 and A2A adenosine receptors in regulating heart rate, body temperature, and locomotion as revealed using knockout mice and caffeine. Am J Physiol Heart Circ Physiol 296: H1141-H1149, 2009.
121. Yang Z, Day YJ, Toufektsian MC, Ramos SI, Marshall M, Wang XQ, French BA, and Linden J. Infarct-sparing effect of A2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation 111: 2190-2197, 2005. (Pubitemid 40632434)
122. Yellon DM and Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 357: 1121-1135, 2007.
123. Zhou Y, Mohsenin A, Morschl E, Young HW, Molina JG, Ma W, Sun CX, Martinez-Valdez H, and Blackburn MR. Enhanced airway inflammation and remodeling in adenosine deaminase-deficient mice lacking the A2B adenosine receptor. J Immunol 182: 8037-8046, 2009.
124. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol 362: 299-309, 2000.